DE10295664D2 - Verfahren zum Nachweis von Morbus Alzheimer und zur Unterscheidung von Morbus Alzheimer gegenüber anderen demenziellen Erkrankungen, zugehörige Paptide und deren Verwendungen - Google Patents
Verfahren zum Nachweis von Morbus Alzheimer und zur Unterscheidung von Morbus Alzheimer gegenüber anderen demenziellen Erkrankungen, zugehörige Paptide und deren VerwendungenInfo
- Publication number
- DE10295664D2 DE10295664D2 DE10295664T DE10295664T DE10295664D2 DE 10295664 D2 DE10295664 D2 DE 10295664D2 DE 10295664 T DE10295664 T DE 10295664T DE 10295664 T DE10295664 T DE 10295664T DE 10295664 D2 DE10295664 D2 DE 10295664D2
- Authority
- DE
- Germany
- Prior art keywords
- alzheimer
- disease
- paptids
- differentiate
- detection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Psychiatry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Hospice & Palliative Care (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10295664T DE10295664D2 (de) | 2001-11-28 | 2002-11-27 | Verfahren zum Nachweis von Morbus Alzheimer und zur Unterscheidung von Morbus Alzheimer gegenüber anderen demenziellen Erkrankungen, zugehörige Paptide und deren Verwendungen |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10158180A DE10158180A1 (de) | 2001-11-28 | 2001-11-28 | Verfahren zum Nachweis von Morbus Alzheimer und zur Unterscheidung von Morbus Alzheimer gegenüber anderen demenziellen Erkrankungen, zugehörige Peptide und deren Verwendung |
DE10295664T DE10295664D2 (de) | 2001-11-28 | 2002-11-27 | Verfahren zum Nachweis von Morbus Alzheimer und zur Unterscheidung von Morbus Alzheimer gegenüber anderen demenziellen Erkrankungen, zugehörige Paptide und deren Verwendungen |
PCT/DE2002/004360 WO2003048775A2 (de) | 2001-11-28 | 2002-11-27 | Peptide und verfahren zum nachweis von morbus alzheimer und zur unterscheidung von morbus alzheimer gegenüber anderen demenziellen erkrankungen |
Publications (1)
Publication Number | Publication Date |
---|---|
DE10295664D2 true DE10295664D2 (de) | 2004-10-14 |
Family
ID=7707147
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE10158180A Ceased DE10158180A1 (de) | 2001-11-28 | 2001-11-28 | Verfahren zum Nachweis von Morbus Alzheimer und zur Unterscheidung von Morbus Alzheimer gegenüber anderen demenziellen Erkrankungen, zugehörige Peptide und deren Verwendung |
DE10295664T Expired - Fee Related DE10295664D2 (de) | 2001-11-28 | 2002-11-27 | Verfahren zum Nachweis von Morbus Alzheimer und zur Unterscheidung von Morbus Alzheimer gegenüber anderen demenziellen Erkrankungen, zugehörige Paptide und deren Verwendungen |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE10158180A Ceased DE10158180A1 (de) | 2001-11-28 | 2001-11-28 | Verfahren zum Nachweis von Morbus Alzheimer und zur Unterscheidung von Morbus Alzheimer gegenüber anderen demenziellen Erkrankungen, zugehörige Peptide und deren Verwendung |
Country Status (7)
Country | Link |
---|---|
US (1) | US20050048584A1 (de) |
EP (1) | EP1451590A2 (de) |
JP (1) | JP2005511063A (de) |
AU (1) | AU2002363825A1 (de) |
CA (1) | CA2467073A1 (de) |
DE (2) | DE10158180A1 (de) |
WO (1) | WO2003048775A2 (de) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7049397B2 (en) * | 2001-04-30 | 2006-05-23 | Syn X Pharma, Inc. | Biopolymer marker indicative of disease state having a molecular weight of 1211 daltons |
DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
WO2005098446A2 (en) * | 2004-03-31 | 2005-10-20 | The Johns Hopkins University | Biomarkers for ovarian cancer |
GB0421639D0 (en) * | 2004-09-29 | 2004-10-27 | Proteome Sciences Plc | Methods and compositions relating to alzheimer's disease |
US8865763B2 (en) | 2005-10-14 | 2014-10-21 | Alltech, Inc. | Methods and compositions for altering cell function |
CN102764279B (zh) * | 2005-10-14 | 2015-04-01 | 全面技术公司 | 改变细胞功能的方法和组合物 |
US8871715B2 (en) | 2005-10-14 | 2014-10-28 | Alltech, Inc. | Use of selenium compounds, especially selenium yeasts for altering cognitive function |
RU2432362C2 (ru) | 2005-11-30 | 2011-10-27 | Эбботт Лэборетриз | Моноклональные антитела и их применения |
BRPI0619249A2 (pt) | 2005-11-30 | 2011-09-20 | Abbott Lab | anticorpos anti-globulÈmeros-aß, frações que se ligam a antìgeno destes, hibridomas correspondentes, ácidos nucléicos, vetores, células hospedeiras, métodos de produzir os ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos de usar os ditos anticorpos |
US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
EP2486928A1 (de) * | 2007-02-27 | 2012-08-15 | Abbott GmbH & Co. KG | Verfahren zur Behandlung von Amyloidosen |
WO2011130377A2 (en) | 2010-04-15 | 2011-10-20 | Abbott Laboratories | Amyloid-beta binding proteins |
WO2012024187A1 (en) | 2010-08-14 | 2012-02-23 | Abbott Laboratories | Amyloid-beta binding proteins |
ES2580136T3 (es) | 2010-12-16 | 2016-08-19 | Autism Biotech Limited | Biomarcador novedoso y usos del mismo en el diagnóstico, tratamiento de autismo |
JP6012923B2 (ja) | 2010-12-22 | 2016-10-25 | 株式会社Mcbi | 認知機能障害疾患のバイオマーカーおよび該バイオマーカーを用いる認知機能障害疾患の検出方法 |
GB201310203D0 (en) * | 2013-06-07 | 2013-07-24 | Electrophoretics Ltd | Materials and methods relating to Alzheimer's disease |
GB2515334A (en) * | 2013-06-20 | 2014-12-24 | Neuro Bio Ltd | Biomarkers for alzheimer's Disease |
US20160018798A1 (en) * | 2014-07-17 | 2016-01-21 | Toyota Motor Engineering & Manufacturing North America, Inc. | Home control system from a vehicle |
EP3654032B1 (de) * | 2017-07-14 | 2023-09-27 | Mcbi Inc. | Verfahren zum nachweis von krankheiten |
JP7457300B2 (ja) * | 2018-08-29 | 2024-03-28 | 国立大学法人 岡山大学 | 神経変性疾患の診断用ペプチドマーカー |
CN114150057B (zh) * | 2021-12-21 | 2024-04-26 | 贾龙飞 | 一种诊断阿尔茨海默病的外泌体蛋白及其用途 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7314717B2 (en) * | 2001-04-30 | 2008-01-01 | Nanogen Inc. | Biopolymer marker indicative of disease state having a molecular weight of 1562 daltons |
US6756476B2 (en) * | 2001-04-30 | 2004-06-29 | Syn X Pharma, Inc. | Biopolymer marker indicative of disease state having a molecular weight of 2021 daltons |
US6617308B2 (en) * | 2001-04-30 | 2003-09-09 | Syn X Pharma, Inc. | Biopolymer marker indicative of disease state having a molecular weight of 1865 daltons |
US20020160420A1 (en) * | 2001-04-30 | 2002-10-31 | George Jackowski | Process for diagnosis of physiological conditions by characterization of proteomic materials |
US20030100016A1 (en) * | 2001-11-23 | 2003-05-29 | George Jackowski | Complement C3 precursor biopolymer markers predictive of Alzheimers disease |
-
2001
- 2001-11-28 DE DE10158180A patent/DE10158180A1/de not_active Ceased
-
2002
- 2002-11-27 DE DE10295664T patent/DE10295664D2/de not_active Expired - Fee Related
- 2002-11-27 JP JP2003549919A patent/JP2005511063A/ja active Pending
- 2002-11-27 CA CA002467073A patent/CA2467073A1/en not_active Abandoned
- 2002-11-27 EP EP02798252A patent/EP1451590A2/de not_active Withdrawn
- 2002-11-27 WO PCT/DE2002/004360 patent/WO2003048775A2/de active Application Filing
- 2002-11-27 AU AU2002363825A patent/AU2002363825A1/en not_active Abandoned
- 2002-11-27 US US10/497,073 patent/US20050048584A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP2005511063A (ja) | 2005-04-28 |
DE10158180A1 (de) | 2003-09-11 |
CA2467073A1 (en) | 2003-06-12 |
AU2002363825A1 (en) | 2003-06-17 |
WO2003048775A2 (de) | 2003-06-12 |
AU2002363825A8 (en) | 2003-06-17 |
US20050048584A1 (en) | 2005-03-03 |
EP1451590A2 (de) | 2004-09-01 |
WO2003048775A3 (de) | 2004-01-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE10295664D2 (de) | Verfahren zum Nachweis von Morbus Alzheimer und zur Unterscheidung von Morbus Alzheimer gegenüber anderen demenziellen Erkrankungen, zugehörige Paptide und deren Verwendungen | |
DE60141671D1 (de) | Vorrichtung, Verfahren und Programmprodukt zur Erfassung und Bereitstellung von Information | |
DE50115197D1 (de) | Verfahren zur herstellung von borstenwaren sowie borstenware | |
DE60002793D1 (de) | Verfahren zur Herstellung von Acrolein und Acrylsäure | |
DE69506496D1 (de) | Verfahren zur Herstellung von modifizierten Harzen und ihre Verwendungen | |
DE60107991D1 (de) | Verfahren zur Herstellung von Titanoxid | |
DE60023128D1 (de) | Pyrazolecarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen | |
DE50204669D1 (de) | Verfahren zur Herstellung von Heissgetränken sowie Vorrichtung zur Durchführung des Verfahrens | |
DE60001770D1 (de) | Verfahren zur Herstellung von eigenleitfähigen Copolymeren und damit hergestellte eigenleitfähige Copolymer-Verbindungen | |
DE50006246D1 (de) | Verfahren und vorrichtung zur herstellung von borstenwaren und danach hergestellte borstenwaren | |
DE69934234D1 (de) | Verfahren zur herstellung von masa-mehle | |
DE60104967D1 (de) | Verfahren zur Herstellung von Seitenfaltenbeuteln | |
DE60307710D1 (de) | Verfahren zur Herstellung von Eisenoxiden | |
DE60121261D1 (de) | Verfahren zur Herstellung von Titanoxid | |
DE60323994D1 (de) | Verfahren zur herstellung von 2-chlor-1,1,1,2,3,3,3-heptafluorpropan, hexafluorpropen und 1,1,1,2,3,3,3-heptafluorpropan | |
DE60104244D1 (de) | Verfahren zur Herstellung von Amiden | |
DE69909181D1 (de) | Verfahren zur Herstellung von Acrolein und Acrylsäure | |
DE69936994D1 (de) | Verfahren zur behandlung von okularen neovaskularen erkrankungen | |
DE69806118T2 (de) | Verbessertes Verfahren zur Herstellung von Propylenoxid und Styren | |
DE60002538D1 (de) | Verfahren zur Herstellung von Cyclododecanon und Cyclododecanol | |
DE60127593D1 (de) | Verfahren zur Herstellung von Membranen und die damit hergestellten Membranen | |
ATE300531T1 (de) | Isonipecotamide zur behandlung von integrin vermittelten störungen | |
DE69921634D1 (de) | Verfahren zur Herstellung von ölige Konzentrate | |
DE69905772T2 (de) | Verfahren zur rückgewinnung von 3,4-epoxy-1-buten | |
DE60208551D1 (de) | Verfahren zur herstellung von racemischen und enantiomerenreinen derivaten von 1,5-diaryl-3-trifluormethyl-delta2-pyrazolinen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8139 | Disposal/non-payment of the annual fee |